Related Experiment Videos
Aging and the hemopoietic system.
Antonio Pinto1, Rosaria De Filippi, Ferdinando Frigeri
1Hematology/Oncology Unit, National Cancer Institute, INT Fondazione "Pascale", IRCCS, Via M. Semmola, I-80131 Naples, Italy. apinto.int.napoli@tin.it
Critical Reviews in Oncology/Hematology
|October 18, 2003
Summary
Older adults face higher risks of severe side effects from chemotherapy due to poorly understood age-related changes in their hematopoietic system. Research aims to uncover these mechanisms to improve cancer treatment strategies for elderly patients.
Area of Science:
- Gerontology
- Hematology
- Oncology
Background:
- Elderly cancer patients experience higher rates of myelosuppression and treatment-related deaths with standard chemotherapy compared to younger individuals.
- The biological mechanisms behind reduced chemotherapy tolerance in the aging hematopoietic system are not fully understood.
- Aging bone marrow changes, though subtle in normal conditions, can impact hematopoietic recovery under stress.
Purpose of the Study:
- To elucidate the mechanisms of age-dependent decline in hematopoietic reserve and chemotherapy tolerance.
- To identify strategies for ameliorating chemotherapy side effects in older cancer patients.
- To explore the role of age-related immune changes and potential immunotherapies for residual disease.
Main Methods:
- Review of current evidence on age-related bone marrow changes and hematopoietic stress response.
- Analysis of age-associated alterations in stem and progenitor cell compartments.
- Evaluation of age-related immune responses, including dendritic cell (DC) function.
Main Results:
- Aging may lead to subtle bone marrow changes that become significant under chemotherapy stress, impairing hematopoietic recovery.
- Age-associated changes in stem and progenitor cells likely contribute to reduced recovery from hematologic stress.
- Dendritic cells from older individuals appear functional, suggesting potential for DC-based immunotherapy.
Conclusions:
- Understanding age-related hematopoietic changes is crucial for optimizing chemotherapy for elderly cancer patients.
- Dendritic cell-based immunotherapy shows promise for treating residual disease in aged populations.
- Growth factor prophylaxis is established, but innovative strategies may enable intensified chemotherapy for specific cancers like non-Hodgkin's lymphomas in older adults.